Abduljawad et al. (2023) conducted a systematic review of 19 articles involving 77 cases, evaluating the effectiveness of IL-17 inhibitors (Secukinumab and ixekizumab) in treating PRP [5]. Here, IL17A is linked to familial pityriasis rubra pilaris.